Skip to content

Cerebrovascular Reactivity in Obstructive Sleep Apnea (OSA) Subjects

Spatial and Temporal Response of Cerebrovascular Response in OSA

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01133717
Enrollment
60
Registered
2010-05-31
Start date
2010-02-28
Completion date
2015-04-30
Last updated
2014-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep Apnea

Keywords

Sleep Apnea, Cerebrovascular Reactivity

Brief summary

Obstructive sleep apnea (OSA) is a prevalent sleep breathing disorder in the general population in which recurrent collapse of the upper airway occurs during sleep. OSA is more prevalent in subjects with stroke and is associated with a 3 fold increased risk of stroke. This makes it a serious public health problem. Approximately 50% of subjects with OSA are asymptomatic and are often only detected following investigation for the cause of heart disease or a stroke. In subjects who are treated for OSA many are intolerant or poorly compliant with treatment. Therefore, the identification of those subjects with OSA most at risk of adverse consequences such as stroke is important, so that treatment compliance can be improved. Therfore, the investigators want to determine if compared to subjects without OSA, subjects with OSA have evidence of increased stroke risk by assessment of changes in cerebral blood flow (cerebrovascular reactivity) as measured on Doppler ultrasound of the middle cerebral artery (TCD) and blood oxygen level-dependent magnetic resonance imaging of patterns of cerebral blood flow (BOLD MRI) to two stimuli. These stimuli include increased carbon dioxide concentrations (causes increased cerebral blood flow) and reduced oxygen concentrations (causing decreased cerebral blood flow). In order to deliver these stimuli the investigators will use a special machine (RespiractTM) which allows for the precise control of carbon dioxide and oxygen concentrations in the lungs and blood. The precise control of carbon dioxide and oxygen in conjunction with BOLD MRI has enabled the production of detailed maps of the brain that identify areas of healthy and abnormal blood supply.

Detailed description

OSA is associated with increased risk of cardiovascular and cerebrovascular disease compared to the general population. The mechanism for the increased stroke risk in OSA is unknown. However, the constellation of adverse pathophysiological consequences, including intermittent hypoxia and carbon-dioxide retention as a result of OSA may be detrimental to CVR and predispose the brain to ischemia. Previous studies in OSA subjects have measured CVR only using TCD. Therefore, our study will examine CVR by two methods (TCD and BOLD-MRI) with reliable and reproducible hypercapnia and independent control of oxygen saturation (RespiractTM). Patterns seen on CVR may eventually allow the identification of OSA patients who will be at greatest risk for stroke and will therefore, require aggressive risk reduction and/or treatment irrespective of symptoms.

Interventions

None listed

Sponsors

University Health Network, Toronto
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Subjects referred for sleep studies

Exclusion criteria

* Known cardiac, neurological or major liver or kidney disease - * Cardioverter/defibrillator metal heart valve or pacemaker * Vascular stent implanted within 6 weeks * Severe claustrophobia * Pregnancy * Shrapnel or history of ophthalmic foreign body * Resting oxygen saturation on room air \< 95% * Insulin-dependent diabetes * Obstructive or restrictive lung disease such that subject is unable to walk up 2 flights of stairs * Major depression.

Design outcomes

Primary

MeasureTime frame
Document the diurnal differences in global CVR as measured by TCD, between those with and without OSABetween 8pm and 7am approximately

Secondary

MeasureTime frame
Use BOLD MRI to quantify global and regional CVR in various regions and vascular territories of the brain in subjects with OSA.one week

Countries

Canada

Contacts

Primary ContactClodagh M Ryan, MD
clodagh.ryan@uhn.on.ca4163404719
Backup ContactAnn battisti, BSc
abattist@uhnres.utoronto.ca

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026